Natural killer cell-based immunotherapy in gynecologic malignancy: A review

Locke D Uppendahl; Carly M. Dahl; Jeffrey S Miller; Martin Felices; Melissa A Geller

doi:10.3389/fimmu.2017.01825

Natural killer cell-based immunotherapy in gynecologic malignancy: A review

Locke D Uppendahl, Carly M. Dahl, Jeffrey S Miller, Martin Felices, Melissa A Geller

Research output: Contribution to journal › Review article › peer-review

46 Scopus citations

Abstract

Harnessing the immune system has proven an effective therapy in treating malignancies. Since the discovery of natural killer (NK) cells, strategies aimed to manipulate and augment their effector function against cancer have been the subject of intense research. Recent progress in the immunobiology of NK cells has led to the development of promising therapeutic approaches. In this review, we will focus on the recent advances in NK cell immunobiology and the clinical application of NK cell immunotherapy in ovarian, cervical, and uterine cancer.

Original language	English (US)
Article number	1825
Journal	Frontiers in immunology
Volume	8
Issue number	JAN
DOIs	https://doi.org/10.3389/fimmu.2017.01825
State	Published - Jan 5 2018

Bibliographical note

Funding Information:
This work was supported by the following grants: NIH R35 CA197292 and U.S. Department of Defense CA150085, the Minnesota Ovarian Cancer Alliance (MOCA) (MG) "NK Cell Immunotherapy for Ovarian Cancer," Mayo Clinic Ovarian Cancer SPORE (P50 CA136393), and by a Research Scholar Grant (RSG-14-151-01-CCE) from the American Cancer Society.

Publisher Copyright:
© 2018 Uppendahl, Dahl, Miller, Felices and Geller.

Keywords

Cervical cancer
Gynecologic malignancy
Immunotherapy
Natural killer cells
Ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.3389/fimmu.2017.01825

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760535

Find It

Find It at U of M Libraries

Cite this

@article{661e0f37156f449c9ad4c3a8d49d0ff4,

title = "Natural killer cell-based immunotherapy in gynecologic malignancy: A review",

abstract = "Harnessing the immune system has proven an effective therapy in treating malignancies. Since the discovery of natural killer (NK) cells, strategies aimed to manipulate and augment their effector function against cancer have been the subject of intense research. Recent progress in the immunobiology of NK cells has led to the development of promising therapeutic approaches. In this review, we will focus on the recent advances in NK cell immunobiology and the clinical application of NK cell immunotherapy in ovarian, cervical, and uterine cancer.",

keywords = "Cervical cancer, Gynecologic malignancy, Immunotherapy, Natural killer cells, Ovarian cancer",

author = "Uppendahl, {Locke D} and Dahl, {Carly M.} and Miller, {Jeffrey S} and Martin Felices and Geller, {Melissa A}",

note = "Funding Information: This work was supported by the following grants: NIH R35 CA197292 and U.S. Department of Defense CA150085, the Minnesota Ovarian Cancer Alliance (MOCA) (MG) {"}NK Cell Immunotherapy for Ovarian Cancer,{"} Mayo Clinic Ovarian Cancer SPORE (P50 CA136393), and by a Research Scholar Grant (RSG-14-151-01-CCE) from the American Cancer Society. Publisher Copyright: {\textcopyright} 2018 Uppendahl, Dahl, Miller, Felices and Geller.",

year = "2018",

month = jan,

day = "5",

doi = "10.3389/fimmu.2017.01825",

language = "English (US)",

volume = "8",

journal = "Frontiers in immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

number = "JAN",

}

TY - JOUR

T1 - Natural killer cell-based immunotherapy in gynecologic malignancy

T2 - A review

AU - Uppendahl, Locke D

AU - Dahl, Carly M.

AU - Miller, Jeffrey S

AU - Felices, Martin

AU - Geller, Melissa A

N1 - Funding Information: This work was supported by the following grants: NIH R35 CA197292 and U.S. Department of Defense CA150085, the Minnesota Ovarian Cancer Alliance (MOCA) (MG) "NK Cell Immunotherapy for Ovarian Cancer," Mayo Clinic Ovarian Cancer SPORE (P50 CA136393), and by a Research Scholar Grant (RSG-14-151-01-CCE) from the American Cancer Society. Publisher Copyright: © 2018 Uppendahl, Dahl, Miller, Felices and Geller.

PY - 2018/1/5

Y1 - 2018/1/5

N2 - Harnessing the immune system has proven an effective therapy in treating malignancies. Since the discovery of natural killer (NK) cells, strategies aimed to manipulate and augment their effector function against cancer have been the subject of intense research. Recent progress in the immunobiology of NK cells has led to the development of promising therapeutic approaches. In this review, we will focus on the recent advances in NK cell immunobiology and the clinical application of NK cell immunotherapy in ovarian, cervical, and uterine cancer.

AB - Harnessing the immune system has proven an effective therapy in treating malignancies. Since the discovery of natural killer (NK) cells, strategies aimed to manipulate and augment their effector function against cancer have been the subject of intense research. Recent progress in the immunobiology of NK cells has led to the development of promising therapeutic approaches. In this review, we will focus on the recent advances in NK cell immunobiology and the clinical application of NK cell immunotherapy in ovarian, cervical, and uterine cancer.

KW - Cervical cancer

KW - Gynecologic malignancy

KW - Immunotherapy

KW - Natural killer cells

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85040032500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040032500&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.01825

DO - 10.3389/fimmu.2017.01825

M3 - Review article

C2 - 29354116

AN - SCOPUS:85040032500

SN - 1664-3224

VL - 8

JO - Frontiers in immunology

JF - Frontiers in immunology

IS - JAN

M1 - 1825

ER -

Natural killer cell-based immunotherapy in gynecologic malignancy: A review

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this